2019 Annual Meeting of the European Association for the Study of the Liver*

EASL 2019 Program Image
Download All
April 10-14, 2019; Vienna, Austria
Get the latest hepatitis and NASH data with rapid Capsule Summaries and downloadable slidesets covering key studies from Vienna.
Nancy Reau, MD
Zobair Younossi Headshot
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Stefan Zeuzem, MD

Highlights

Listen as expert faculty discusses the clinical impact of the most important NAFLD/NASH data from the Vienna meeting.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: May 2, 2019

Listen to expert commentary on the clinical impact of data from the Vienna meeting regarding treatment of viral hepatitis and progress toward HCV elimination.

Stefan Zeuzem, MD Released: May 10, 2019
Slidesets STOP Study: Incidence and Predictors of ALT Flares in HBeAg-Negative Patients Discontinuing NA Therapy for CHB
Slidesets Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia
Slidesets Interim Analysis of Phase III REGENERATE: Obeticholic Acid vs Placebo for NASH
Slidesets Phase II Trial of Emricasan in NASH Cirrhosis and Severe Portal Hypertension
Slidesets Lower Risk of Hepatocellular Carcinoma With TDF vs ETV in Patients With Chronic Hepatitis B From Large Hong Kong Database Analysis
Slidesets Efficacy of HCV Treatment in a Large Clinical Cohort From the English National HCV Registry
Slidesets Retrospective Analysis Identifies Numerous Gaps Along HCV Care Cascade Across Physician Specialties in the US
Slidesets Pilot Study of Same-Day Testing and Treatment of HCV and HBV in Egyptian Village
Slidesets ETHOS Engage Study: Uptake of HCV Testing and Treatment Among People Who Inject Drugs in Australia
Slidesets SMART-C: Standard vs Simplified Monitoring of Initial HCV Treatment With Glecaprevir/Pibrentasvir

Expert faculty members summarize key studies on hepatitis C treatment and elimination, hepatitis B treatment, NASH/NAFLD clinical impact, and NASH treatment studies from this important annual conference.

Nancy Reau, MD Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Stefan Zeuzem, MD Released: April 30, 2019
Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue